中国临床药理学杂志2012，Vol.28Issue(9)：682-684,3.
阿立哌唑与氯丙嗪治疗精神分裂症的安全性系统评价
Systematic review the safety of aripiprazole versus clorpromazine in the treatment of schizophrenia
摘要
Abstract
Objective To study the difference in adverse drug reaction ( ADR) between aripiprazole and clorpromazine in the treatment of schizophrenia. Methods A total of 10 paper about control study comparing aripiprazole with clorpromazine in treatment of schizophrenia retrieved were subjected to system evaluation. Results There was significant difference in ADR incidences between the two groups ( P < 0. 05 ). The incidences of ADR ( such as headache insomnia) in aripiprazole group were significantly higher than in clorpromazine group (P < 0. 05 ). The incidences of ADR ( such as dry mouth, tremor, akathisia, rigidity, constipation, abnormal, liver function, tachycardia, weight gain, orthostatic hypotension, blurred vision, drowsiness, menstruation disturbance syndrome) in clorpromazine group were significantly higher than in aripiprazole group ( P < 0. 05 ). Conclusion Aripiprazole has less overall risk of ADR than clorpromazine for the treatment of schizophrenia.关键词
阿立哌唑/氯丙嗪/精神分裂症/安全性Key words
aripiprazole/ clorpromazine/ schizophrenia/ safety分类
医药卫生引用本文复制引用
杜彪,李庆平,母波,刘福,周春阳..阿立哌唑与氯丙嗪治疗精神分裂症的安全性系统评价[J].中国临床药理学杂志,2012,28(9):682-684,3.基金项目
重庆市万州区科学技术基金资助项目(20084011) （20084011）
